Moreover , in patients treated with clopidogrel predominantly for percutaneous coronary intervention , carriers of 1 or 2 CYP2C19 loss-of-function alleles are at increased risk for major adverse cardiovascular outcomes , with an 1.5-fold increase in the risk of cardiovascular death , myocardial infarction , or stroke as well as an 3-fold increase in risk for stent thrombosis .